SCHEMBL19815033

SCHEMBL19815033

O=C(O)N1CCC(=O)C2(CCCC2)C1

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.31
DDB1 Q16531 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19815023 0.98 KMT2A (0.33) CRBNDDB1MEN1KMT2A
SCHEMBL19815096 0.96 CRBN (0.31) CRBNDDB1
SCHEMBL2159192 0.92 CRBN (0.33) CRBNDDB1
SCHEMBL19817308 0.84 ALDH1A1 (0.34)
SCHEMBL17112824 0.82 DDB1 (0.30) CRBNDDB1
SCHEMBL17611698 0.78 CRBN (0.40) CRBNDDB1
SCHEMBL18321890 0.78 SPR (0.36) CRBNDDB1MEN1KMT2A
SCHEMBL4985158 0.76 USP30 (0.44) CRBNDDB1MEN1KMT2A
SCHEMBL5895840 0.76 SPR (0.35) CRBNDDB1
SCHEMBL21197351 0.75 USP30 (0.43) CRBNDDB1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313295-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2024-02-07 EP disclosed
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-11-07 US disclosed
WO-2022200523-A9 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-02-16 WO disclosed
EP-3746432-B1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LTD (GB) 2022-12-14 EP disclosed
EP-3490982-B1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LTD (GB) 2022-04-20 EP disclosed
US-20220033397-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LTD (GB) 2022-02-03 US disclosed
US-20220002264-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2022-01-06 US disclosed
EP-3890829-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2021-10-13 EP disclosed
US-11053213-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2021-07-06 US disclosed
US-20210070773-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2021-03-11 US disclosed
EP-3746432-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2020-12-09 EP disclosed
WO-2020115501-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2020-06-11 WO disclosed
WO-2019150119-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2019-08-08 WO disclosed
US-20190233394-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2019-08-01 US disclosed
EP-3490982-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2019-06-05 EP disclosed
WO-2018020242-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2018-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233394-A1 PHARMACEUTICAL COMPOUNDS USP19, USP18, UBE2I CRBN 422/4885DDB1 2736/4885MEN1 2163/4885
US-20220033397-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) USP19, USP16, USP18 CRBN 251/4885DDB1 2283/4885MEN1 3585/4885
US-20220002264-A1 PHARMACEUTICAL COMPOUNDS USP19, USP18, UBE2I CRBN 422/4885DDB1 2736/4885MEN1 2163/4885
US-11053213-B2 Pharmaceutical compounds USP19, USP18, UBE2I CRBN 422/4885DDB1 2736/4885MEN1 2163/4885
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) USP19, USP16, USP18 CRBN 770/4885DDB1 1053/4885MEN1 4318/4885
US-20210070773-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) USP19, USP16, USP18 CRBN 770/4885DDB1 1053/4885MEN1 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.